期刊文献+

基于T_(>MIC)的美罗培南的给药方案建立 被引量:9

Dosage regimens of meropenem based on T_(>MIC)
原文传递
导出
摘要 目的:建立T〉MIC超过40%的美罗培南给药设计方案。方法:估算患者药动学参数,以T〉MIC达到40%~100%为目标,利用药动学公式和简易数学法设计给药方案,比较实测Cmax、Cmin与预测值的差别,并分别计算药时曲线法和简易数学模拟法下的T〉MIC。结果:患者预测Cmin为(1.6±0.9)μg·ml-1,实际Cmin为(1.8±1.6)μg·ml-1,预测Cmax为(23.2±8.8)μg·ml-1,实际Cmax为(26.8±13.3)μg·ml-1,预测Cmin、Cmax与实际Cmin、Cmax均具有相关性(P〈0.001,r=0.695;P〈0.001,r=0.874);患者药时曲线模拟法的T〉MIC与简单数学模拟法的T〉MIC具有高相关性(P〈0.001,r=0.968),校正公式为:Y=1.116 X-12.28。30例患者中仅有2例的T〉MIC没有达到目标范围。结论:本方案简便,快捷,可用于临床美罗培南个体化给药方案的设计及评价。 OBJECTIVE To establish meropenem dosage regimens based on T〉MIC of 40% - 100%. METHODS The pharmacokinetic parameters of patients were estimated, meropenem dosage regimes were designed according to pharmacokinetic parameters and T〉MIC of 40% - 100%. T〉MIC was calculated by simple mathematical simulation and concentration-time curves simulation. Predicted Cram and Cmax were compared with observed Cmin, and Cmaxrespectively. T〉MIC calculated by simple mathematical simulation was compared to that calculated by concentration-time curves simulation. RESULTS Predicted Cmin and Cmax were (1.6 ± 0.9) /μg.ml -1 and (23.2 -± 8.8) μg.ml-1 respectively, observed Cmin and C were (1. 8 ± 1.6)μg.ml / and(26. 8 ± 13.3)μg. ml-1, respectively. There was correlation between predicted values and measured values. Correlation was also found between T〉MIC calculated by simple mathematical simulation and by concentration time curves simulation. Correction formula was Y = 1.116X- 12.28. In all 30 patients, only two patients' T〉MIC Was out of the target range. CONCLUSION The established dosage regimens of meropenem was convenient, it was suitable for individual dosage regimen design of meropenem based on T〉MIC.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第1期69-73,共5页 Chinese Journal of Hospital Pharmacy
基金 长沙市科技计划项目(项目编号:K1301012-31)
关键词 美罗培南 T〉MIC 给药方案 meropenem T〉MIC dosage regimen
  • 相关文献

参考文献13

  • 1KarageorgopoulosDE,Falagas ME. Current control and treatmem of muhidrug-resistant acinetobacter baumannii infections[J].{H}LANCET INFECTIOUS DISEASES,2008,(12):751-762. 被引量:1
  • 2Peleg AY,Hooper DC. Hospital-acquired infections due to gram-negative bacteria[J].{H}New England Journal of Medicine,2010,(19):1804-1813. 被引量:1
  • 3Crandon JL,Ariano RE,Zelenitsky SA. Optimization of mempenem dosage in the critically ill population based on renal function[J].{H}Intensive Care Medicine,2011,(04):632-638. 被引量:1
  • 4Ohata Y,Tomita Y,Nakayama M. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations[J].{H}Drug Metabolism and Pharmacokinetics,2011,(05):523-531. 被引量:1
  • 5Nishikawa G,Ikawa K,Nakamura K. Prostatic penetration of meropenem in humans,and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation[J].lm J Antimicrob Agents,2013,(03):267-271. 被引量:1
  • 6杨阳,李昕,王林,徐兵.基于PK/PD参数的碳青霉烯类药物给药方案设计[J].中南药学,2013,11(2):157-159. 被引量:15
  • 7楼永海,徐颖鹤,周雅芳.高效液相色谱法测定人血清和置换液中美罗培南浓度[J].中国医院药学杂志,2007,27(12):1692-1694. 被引量:7
  • 8Zhou QT,He B,Zhang C. Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections:population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics st udy[J].{H}Drugs & aging,2011,(11):903-912. 被引量:1
  • 9Li C,Kuti JL,Nightingale CH. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients[J].J Clin Pharrnacol,2006,(10):1171-1178. 被引量:1
  • 10Lee DG,Choi SM,Shin WS. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea[J].{H}International Journal of Antimicrobial Agents,2006,(04):333-339.doi:10.1016/j.ijantimicag.2006.05.033. 被引量:1

二级参考文献13

  • 1Ozkan Y, Kucukguzel L, Ozkan SA, et al. A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form human serum and urine[J]. Biomedical Chromatography,2001,15(4) : 被引量:1
  • 2Sutep J, Somchai S. Comparison .of the pharmacodynamics of meropenem in heathy volunteers following adminstration by intermittent infusion or bolus injection[J]. Journal of Antimicro bial Chemotherapy,2003,52(3) :518-521. 被引量:1
  • 3Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis[J]. Clin Pharmacokinet,2005, 44: 539-549. 被引量:1
  • 4Lee LS,Kinzig-Schippers M,Nafziger AN,et al.Comparisonof 30-min and 3-h infusion regimens for imipenem/cilastatin and formeropenem evaluated by Monte Carlo simulation[J].Diagn Micro-biol Infect Dis,2010,68(3):251-258. 被引量:1
  • 5Li C,Kuti JL,Nightingale CH,et al.Population pharmacoki-netic analysis and dosing regimen optimization of meropenem inadult patients[J].J Clin Pharmacol,2006,46(10):1171-1178. 被引量:1
  • 6Zhou QT,He B,Zhang C,et al.Pharmacokinetics and pharma-codynamics of meropenem in elderly chinese with lower respira-tory tract infections:population pharmacokinetics analysis usingnonlinear mixed-effects modelling and clinical pharmacodynamicsstudy[J].Drugs Aging,2011,28(11):903-912. 被引量:1
  • 7Lee DG,Choi SM,Shin WS,et al.Population pharmacokineticsof meropenem in febrile neutropenic patients in Korea[J].Int J Anti-microb Agents,2006,28(4):333-339. 被引量:1
  • 8Doh K,Woo H,Hur J,et al.Population pharmacokinetics ofmeropenem in burn patients[J].J Antimicrob Chemother,2010,65(11):2428-2435. 被引量:1
  • 9Du X,Li C,Kuti JL,et al.Population pharmacokinetics andpharmacodynamics of meropenem in pediatric patients[J].J ClinPharmacol,2006,46(1):69-75. 被引量:1
  • 10Yoshizawa K,Ikawa K,Ikeda K,et al.Optimisation of imipe-nem regimens in patients with impaired renal function by pharmaco-kinetic-pharmacodynamic target attainment analysis of plasma andurinary concentration data[J].Int J Antimicrob Agents,2012,40(5):427-433. 被引量:1

共引文献20

同被引文献51

引证文献9

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部